Kimberly M Davis1, Scott P Kelly2, George Luta3, Catherine Tomko2, Anthony B Miller4, Kathryn L Taylor2. 1. Lombardi Comprehensive Cancer Center, Georgetown University Medical Center. Electronic address: kmd54@georgetown.edu. 2. Lombardi Comprehensive Cancer Center, Georgetown University Medical Center. 3. Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center. 4. Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, ON, Canada.
Abstract
OBJECTIVE: To examine the association between treatment-related side effects and cancer-specific and general quality of life (QOL) among long-term prostate cancer survivors. MATERIALS AND METHODS: Within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, we conducted telephone interviews with prostate cancer survivors (N = 518) who were 5-10 years after diagnosis. We assessed demographic and clinical information, sexual, urinary, and bowel treatment-related side effects (Expanded Prostate Cancer Index Composite), cancer-specific QOL (Functional Assessment of Cancer Therapy--total score), and general QOL (the Medical Outcomes Study Short Form 12's physical and mental subscales). RESULTS: Participants were aged 74.6 years on average, primarily White (88.4%), and married (81.7%). Pearson correlation coefficients between the 3 treatment-related side effect domains (urinary, sexual, and bowel) and QOL ranged between 0.14 and 0.42 (P <.0001). Multivariable linear regression analyses revealed that poorer urinary and sexual functioning and greater bowel side effects were independently associated with poorer cancer-specific QOL (P <.0001). Bowel and urinary functions were also associated with poorer general QOL on the Medical Outcomes Study Short Form 12's physical component summary and mental component summary (P <.05). Bowel side effects demonstrated the strongest association with all QOL outcomes. CONCLUSION: Treatment-related side effects persisted for up to 10 years after diagnosis and continued to be associated with men's QOL. These results suggest that each of the treatment-related side effects was independently associated with cancer-specific QOL. Compared with the other Expanded Prostate Cancer Index Composite domains, bowel side effects had the strongest association with cancer-specific and general QOL. These associations emphasize the tremendous impact that bowel side effects continue to have for men many years after their initial diagnosis.
OBJECTIVE: To examine the association between treatment-related side effects and cancer-specific and general quality of life (QOL) among long-term prostate cancer survivors. MATERIALS AND METHODS: Within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, we conducted telephone interviews with prostate cancer survivors (N = 518) who were 5-10 years after diagnosis. We assessed demographic and clinical information, sexual, urinary, and bowel treatment-related side effects (Expanded Prostate Cancer Index Composite), cancer-specific QOL (Functional Assessment of Cancer Therapy--total score), and general QOL (the Medical Outcomes Study Short Form 12's physical and mental subscales). RESULTS:Participants were aged 74.6 years on average, primarily White (88.4%), and married (81.7%). Pearson correlation coefficients between the 3 treatment-related side effect domains (urinary, sexual, and bowel) and QOL ranged between 0.14 and 0.42 (P <.0001). Multivariable linear regression analyses revealed that poorer urinary and sexual functioning and greater bowel side effects were independently associated with poorer cancer-specific QOL (P <.0001). Bowel and urinary functions were also associated with poorer general QOL on the Medical Outcomes Study Short Form 12's physical component summary and mental component summary (P <.05). Bowel side effects demonstrated the strongest association with all QOL outcomes. CONCLUSION: Treatment-related side effects persisted for up to 10 years after diagnosis and continued to be associated with men's QOL. These results suggest that each of the treatment-related side effects was independently associated with cancer-specific QOL. Compared with the other Expanded Prostate Cancer Index Composite domains, bowel side effects had the strongest association with cancer-specific and general QOL. These associations emphasize the tremendous impact that bowel side effects continue to have for men many years after their initial diagnosis.
Authors: Kathryn L Taylor; George Luta; Anthony B Miller; Timothy R Church; Scott P Kelly; Larry R Muenz; Kimberly M Davis; David L Dawson; Sara Edmond; Douglas Reding; Jerome E Mabie; Thomas L Riley Journal: J Clin Oncol Date: 2012-06-25 Impact factor: 44.544
Authors: Gerald L Andriole; David L Levin; E David Crawford; Edward P Gelmann; Paul F Pinsky; David Chia; Barnett S Kramer; Douglas Reding; Timothy R Church; Robert L Grubb; Grant Izmirlian; Lawrence R Ragard; Jonathan D Clapp; Philip C Prorok; John K Gohagan Journal: J Natl Cancer Inst Date: 2005-03-16 Impact factor: 13.506
Authors: Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg Journal: N Engl J Med Date: 2009-03-18 Impact factor: 91.245
Authors: Matthew J Resnick; Tatsuki Koyama; Kang-Hsien Fan; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Arnold L Potosky; Janet L Stanford; Antoinette M Stroup; R Lawrence Van Horn; David F Penson Journal: N Engl J Med Date: 2013-01-31 Impact factor: 91.245
Authors: Stephanie L Pugh; Joseph P Rodgers; Katherine A Yeager; Ronald C Chen; Benjamin Movsas; Roseann Bonanni; James Dignam; Deborah W Bruner Journal: Int J Radiat Oncol Biol Phys Date: 2020-06-24 Impact factor: 7.038
Authors: Na Zhang; Richard Fielding; Inda Soong; Karen K K Chan; Janice Tsang; Victor Lee; Conrad Lee; Alice Ng; Wing Kin Sze; Pamela Tin; Wendy Wing Tak Lam Journal: Support Care Cancer Date: 2015-08-28 Impact factor: 3.603
Authors: Gwendolyn P Quinn; Julian A Sanchez; Steven K Sutton; Susan T Vadaparampil; Giang T Nguyen; B Lee Green; Peter A Kanetsky; Matthew B Schabath Journal: CA Cancer J Clin Date: 2015-07-17 Impact factor: 508.702
Authors: Frank J Penedo; Michael H Antoni; Patricia I Moreno; Lara Traeger; Dolores Perdomo; Jason Dahn; Gregory E Miller; Steve Cole; Julian Orjuela; Edgar Pizarro; Betina Yanez Journal: Contemp Clin Trials Date: 2018-07-09 Impact factor: 2.226
Authors: Shi-Yi Wang; Sylvia H Hsu; Cary P Gross; Tara Sanft; Amy J Davidoff; Xiaomei Ma; James B Yu Journal: Value Health Date: 2016-04-07 Impact factor: 5.725
Authors: Linda Trinh; Shabbir M H Alibhai; Nicole Culos-Reed; Catherine M Sabiston; Jennifer M Jones; Dori E Rosenberg; Alexis Whitehorn; Denise Bastas; Guy E Faulkner Journal: J Behav Med Date: 2022-01-21